Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Mol Cancer Ther

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    November 2022
  1. WILDEY G, Shay AM, McColl KS, Yoon S, et al
    Retinoblastoma expression and targeting by CDK4/6 inhibitors in small cell lung cancer.
    Mol Cancer Ther. 2022 Nov 18. pii: 711075. doi: 10.1158/1535-7163.MCT-22-0365.
    PubMed     Abstract available


    October 2022
  2. CROWLEY EA, Hermance NM, Herlihy CP, Manning AL, et al
    Suppression of Chromosome Instability Limits Acquired Drug Resistance.
    Mol Cancer Ther. 2022;21:1583-1593.
    PubMed     Abstract available


    September 2022
  3. CASTELLANO GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, et al
    Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Mol Cancer Ther. 2022;21:1381-1392.
    PubMed     Abstract available


    July 2022
  4. SUN Y, Zhang Y, Schultz CW, Pommier Y, et al
    CDK7 inhibition synergizes with topoisomerase I inhibition in small cell lung cancer cells by inducing ubiquitin-mediated proteolysis of RNA polymerase II.
    Mol Cancer Ther. 2022 Jul 13. pii: 706999. doi: 10.1158/1535-7163.MCT-21-0891.
    PubMed     Abstract available


  5. DU Y, Chen Y, Wang Y, Chen J, et al
    HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
    Mol Cancer Ther. 2022;21:1060-1066.
    PubMed     Abstract available


  6. MARTIN AL, Anadon CM, Biswas S, Mine JA, et al
    Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors.
    Mol Cancer Ther. 2022;21:1184-1194.
    PubMed     Abstract available


    June 2022
  7. WIEDEMEYER WR, Gavrilyuk J, Schammel A, Zhao X, et al
    ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors.
    Mol Cancer Ther. 2022;21:986-998.
    PubMed     Abstract available


  8. ADASHEK JJ, Menta AK, Reddy NK, Desai AP, et al
    Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
    Mol Cancer Ther. 2022;21:871-878.
    PubMed     Abstract available


  9. COKER EA, Stewart A, Ozer B, Minchom A, et al
    Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
    Mol Cancer Ther. 2022;21:1020-1029.
    PubMed     Abstract available


    May 2022
  10. WERR L, Plenker D, Dammert MA, Lorenz C, et al
    CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
    Mol Cancer Ther. 2022;21:821-830.
    PubMed     Abstract available


    April 2022
  11. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
    Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
    Mol Cancer Ther. 2022;21:700.
    PubMed    


  12. CASAZZA A, Van Helleputte L, Van Renterghem B, Pokreisz P, et al
    PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index.
    Mol Cancer Ther. 2022;21:568-581.
    PubMed     Abstract available


  13. KENNEDY GT, Azari FS, Bernstein E, Nadeem B, et al
    A Prostate-Specific Membrane Antigen-Targeted Near-Infrared Conjugate for Identifying Pulmonary Squamous Cell Carcinoma during Resection.
    Mol Cancer Ther. 2022;21:546-554.
    PubMed     Abstract available


    January 2022
  14. JENSEN-PERGAKES K, Tatlock J, Maegley KA, McAlpine IJ, et al
    SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
    Mol Cancer Ther. 2022;21:3-15.
    PubMed     Abstract available


    December 2021
  15. JO H, Yagishita S, Hayashi Y, Ryu S, et al
    Comparative study on the efficacy and exposure of molecular target agents in non-small cell lung cancer PDX models with driver genetic alterations.
    Mol Cancer Ther. 2021 Dec 15. pii: 1535-7163.MCT-21-0371.
    PubMed     Abstract available


  16. BREHMER D, Beke L, Wu T, Millar HJ, et al
    Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
    Mol Cancer Ther. 2021;20:2317-2328.
    PubMed     Abstract available


    October 2021
  17. DASILVA JO, Yang K, Surriga O, Nittoli T, et al
    A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
    Mol Cancer Ther. 2021;20:1966-1976.
    PubMed     Abstract available


    September 2021
  18. YIN L, Zhang Y, Yin L, Ou Y, et al
    Novel mitochondria-based targeting restores responsiveness in therapeutically resistant human lung cancer cells.
    Mol Cancer Ther. 2021 Sep 28. pii: 1535-7163.MCT-20-1095.
    PubMed     Abstract available


  19. JUDD J, Abdel Karim N, Khan H, Naqash AR, et al
    Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2021 Sep 13. pii: 1535-7163.MCT-21-0201.
    PubMed     Abstract available


  20. JIANG Y, Willmore E, Wedge SR, Ryan AJ, et al
    DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.
    Mol Cancer Ther. 2021;20:1663-1671.
    PubMed     Abstract available


  21. LEI K, Kang SS, Ahn EH, Chen C, et al
    C/EBPbeta/AEP Signaling Regulates the Oxidative Stress in Malignant Cancers, Stimulating the Metastasis.
    Mol Cancer Ther. 2021;20:1640-1652.
    PubMed     Abstract available


  22. GILL SJ, Wijnhoven PWG, Fok JHL, Lloyd RL, et al
    Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
    Mol Cancer Ther. 2021;20:1614-1626.
    PubMed     Abstract available


    August 2021
  23. LI Y, Zhang Y, Yu X, Liu Q, et al
    SAGE1: a potential target antigen for lung cancer T-cell immunotherapy.
    Mol Cancer Ther. 2021 Aug 31. pii: 1535-7163.MCT-21-0203.
    PubMed     Abstract available


  24. MERCER-SMITH AR, Jiang W, Bago JR, Valdivia A, et al
    Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.
    Mol Cancer Ther. 2021 Aug 25. pii: 1535-7163.MCT-21-0109.
    PubMed     Abstract available


  25. BASCHNAGEL AM, Elnaggar JH, VanBeek HJ, Kromke AC, et al
    ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient derived xenografts.
    Mol Cancer Ther. 2021 Aug 19. pii: 1535-7163.MCT-21-0305.
    PubMed     Abstract available


  26. FUJIWARA T, Yakoub MA, Chandler A, Christ AB, et al
    CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Mol Cancer Ther. 2021;20:1388-1399.
    PubMed     Abstract available


  27. SURMAN DR, Xu Y, Lee MJ, Trepel J, et al
    Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
    Mol Cancer Ther. 2021;20:1469-1480.
    PubMed     Abstract available


  28. JO U, Senatorov IS, Zimmermann A, Saha LK, et al
    Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
    Mol Cancer Ther. 2021;20:1431-1441.
    PubMed     Abstract available


  29. SMITH RA, Zammit DJ, Damle NK, Usansky H, et al
    ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
    Mol Cancer Ther. 2021;20:1327-1337.
    PubMed     Abstract available


    July 2021
  30. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
    Protein phosphatase 2A as a therapeutic target in small cell lung cancer.
    Mol Cancer Ther. 2021 Jul 12. pii: 1535-7163.MCT-21-0013.
    PubMed     Abstract available


    June 2021
  31. ZHANG D, Hou Z, Aldrich KE, Lockwood L, et al
    A novel Nrf2 pathway inhibitor sensitizes Keap1-mutant lung cancer cells to chemotherapy.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-21-0210.
    PubMed     Abstract available


  32. KANO H, Ichihara E, Watanabe H, Nishii K, et al
    SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naive ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-20-0965.
    PubMed     Abstract available


  33. TANG TT, Konradi AW, Feng Y, Peng X, et al
    Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma.
    Mol Cancer Ther. 2021;20:986-998.
    PubMed     Abstract available


    May 2021
  34. SUN D, Nikonova AS, Zhang P, Deneka AY, et al
    Evaluation of the small-molecule BRD4-degrader CFT-2718 in small cell lung cancer and pancreatic cancer models.
    Mol Cancer Ther. 2021 May 27. pii: 1535-7163.MCT-20-0831.
    PubMed     Abstract available


    May 2020
  35. ZENKE FT, Zimmermann A, Sirrenberg C, Dahmen H, et al
    Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
    Mol Cancer Ther. 2020;19:1091-1101.
    PubMed     Abstract available


  36. YAMASHITA D, Minata M, Ibrahim AN, Yamaguchi S, et al
    Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
    Mol Cancer Ther. 2020;19:1134-1147.
    PubMed     Abstract available


    April 2020
  37. KOTANIDES H, Sattler RM, Lebron MB, Carpenito C, et al
    Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
    Mol Cancer Ther. 2020;19:988-998.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: